Caution is therefore advised when PegIntron treatment is initiated for chronic hepatitis in patients treated with medication with a narrow therapeutic window and sensitive to mild metabolic impairment of the liver.
Seetõttu tuleb olla ettevaatlik kui PegIntron ravi alustatakse kroonilise hepatiidi raviks patsientidel, kes samaaegselt saavad kitsa terapeutilise indeksiga ning maksa metaboolse funktsiooni kerge kahjustuse suhtes tundlikke ravimeid.